AKTIEN IM FOKUS: Übernahme von Aetna setzen CVS-Health-Aktien unter Druck - Älteste Beiträge zuerst (Seite 3) | Diskussion im Forum

[Boersenfreund9]

CVS hat charttechnisch alle Widerstände nach unten durchbrochen. Letzter Widerstand 57 USD

Mal sehen wo die Haltelinie ist. Sollte es auf das Kursniveau von 46 USD gehen, pendeln wir wieder in der Preisrange von 2012.

[faultcode]

nun auch hier mit Cannabis

Größte Apotheken-Kette der USA steigt ins Cannabis-Geschäft ein
https://www.wallstreet-online.de/nachricht/11326422-s-p-500-…

=>
...CVS Pharmacy, mit mehr als 9.800 Filialen die größte Apotheken-Kette der USA, steigt ins Cannabis-Geschäft ein.

In US-Bundesstaaten, in denen Cannabis legalisiert wurde, wird die Apotheken-Kette ab sofort Produkte mit dem nicht-psychoaktiven Hanf-Inhaltsstoff Cannabidiol (CBD) verkaufen.

Dies berichtet der US-Nachrichtensender "CNBC". Die Apotheken-Kette erklärte, dass sie auf CBD-basierte Salben, Cremes, Sprays, Roll-ons und Lotionen im Programm hat. Diese Produkte sind in CVS-Apotheken in acht US-Bundesstaaten erhältlich: Alabama, Kalifornien, Colorado, Illinois, Indiana, Kentucky, Maryland und Tennessee.

CVS Pharmacy ist eine Unternehmenstochter von CVS Health, ein im S&P 500 gelistetes Unternehmen. CVS erklärte, dass sie keine CBD-haltigen Lebensmittelzusatzstoffe oder Nahrungsergänzungsmittel verkaufen wird.

In einer Pressemitteilung des Konzerns heißt es: "Wir sind eine Partnerschaft mit CBD-Produzenten eingegangen, die die geltenden Gesetze einhalten und die die hohen Qualitätsstandards von CVS erfüllen"...

[Globetrotter1]

Fantastische Aussichten

Die planen den Verkauf von cannabisprodukte in acht Bundesstaaten.https://www.wallstreet-online.de/nachricht/11328933-top-news… insgesamt hat CVS 500 Apotheken. Ich glaube damit ist alles gesagt um sich dieses WERTpapier ins Depot zu legen. Das wird uns noch sehr viel Freude bereiten

[Globetrotter1]

Update Die planen nicht sondern es ist bereits soweit. Bis zum heutigen Tage werden insgesamt 800 Apotheken mit der Ware beliefert. https://www.investopedia.com/cvs-selling-cbd-products-curale…

[rtupp]

CVS and Walgreens to Sell CBD Products Despite the FDA’s Growing Concerns

https://www.thecannabisinvestor.ca/cvs-and-walgreens-to-sell…

[faultcode]

CVS Health raises full-year profit forecast on Aetna strength

1.5.
https://finance.yahoo.com/news/cvs-health-beats-profit-estim…

=>
...CVS Health Corp on Wednesday raised its full-year profit forecast and reported first-quarter earnings that topped Wall Street estimates due to growth in its Aetna health insurance business, and as drug prices fell within its expectations.

Shares rose more than 5 percent to $57.35. They had fallen 17 percent this year, hurt by a weak forecast in February and a cut to rival Walgreen Boots Alliance's full-year outlook last month due to lower generic drug prices.

Aetna, CVS's health insurance unit, beat analysts' consensus by more than a billion dollars in the quarter, helped by its accounting for lower medical costs than anticipated during the fourth quarter.

The company, which bought Aetna for $69 billion in November, said 2019 cost savings from the deal were tracking near the high end of its $300 million to $350 million range, and that 2020 savings would likely exceed its $750 million target...

[rtupp]

Big-Box Retailers Walmart and Target Could be Set to Enter the CBD Frenzy

https://www.thecannabisinvestor.ca/big-box-retailers-walmart…

[rtupp]

FDA Under Pressure, New CBD Rules to be Announced on Friday

https://www.thecannabisinvestor.ca/fda-under-pressure-new-cb…

[Kingdeal]

Strong Buy wenn Notenbank Zins senkt wegen Handelsstreik imo

[faultcode]

Antwort auf Beitrag Nr.: 60.467.324 von faultcode am 02.05.19 00:43:25

Stocks of drug distributors and PBM-owners surge after Trump administration pulls rebate proposal

July 11, 2019 10:42 a.m. ET
https://www.marketwatch.com/story/stocks-of-drug-distributor…

=>
...Shares of drug distributors and pharmacy-benefit-manager owners got a boost on Thursday after the Trump administration said it would be withdrawing its plan to overhaul the rebates that drugmakers give to middlemen in Medicare.

The administration, which is making lowering drug costs for Americans a key priority, had said such a proposal would help drive down the prices people pay for prescription medications. However, that would have been a blow to drug distributors and pharmacy-benefit managers, or PBMs.

PBMs act as middlemen between drugmakers and insurance plans, negotiating discounted prices on branded prescription drugs in the form of a rebate. However, PBMs end up pocketing some of those rebates for themselves. The proposal looked to direct those discounts toward patients instead.

“The rule has been an overhang for... stocks for well over a year,” Evercore ISI’s Ross Muken wrote in a note to clients. “Its withdrawal is positive news for companies in the drug channel with economics tied to higher gross list prices, including PBMs and their parent companies, distributors and pharmacies.”

...

The pulling of the proposal comes after a federal judge on Monday blocked a plan put forth by the Trump administration requiring drugmakers to disclose their drug prices in television ads. It was another part of the president’s plan to lower drug costs.

The administration is still looking at ways to lower those costs. Just last week, the president said he was planning to issue an executive order allowing the U.S. to buy drugs based on the lowest price paid by other developed countries.